Peripheral blood CD34+ enumeration as predictor for autologous hematopoietic progenitor cell (HPC) collection in children  by Daum, C.D. et al.
ing their unfamiliarity with this new method of stem cell mobili-
zation. The patients appreciated the inpatient RN’s assistance in
this protocol but were initially dissatisﬁed with the lack of privacy
on a busy inpatient unit. A private area on the inpatient unit was
later secured for study patients to be assessed and monitored. The
administration schedule created some frustration on the part of the
patients due to the long delay between study drug injection and
apheresis. Nevertheless, accrual to this trial at our institution has
been relatively brisk. Patient education, nursing coordination, and
collaboration with members of the BMT team were paramount in
our successful implementation of this study. Designated nursing
staff committed to clinical trials, as well as detailed, mandatory
inservices need to occur in order to implement a complex BMT
trial such as this. Our experience with this trial leads us to conclude
that in order to determine whether patients may beneﬁt from novel
BMT strategies, effective nursing teamwork, education, and col-
laboration will be essential.
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REDUCING ADMISSION RATES POST-STEM CELL TRANSPLANT UTILIZ-
ING AN EDUCATIONAL QUESTIONNAIRE TO ASSESS RETENTION OF
CAREGIVER KNOWLEDGE
Chadakhtzian, A., Barnes, Y., Hayashi, R.J., Shenoy, S. 1. Saint Louis
Children’s Hospital, Saint Louis, MO; 2. Washington University School
of Medicine, Saint Louis, MO.
Background and Aim: Caregivers and recipients of stem cell
transplants (SCT) undergo an educational process to understand,
anticipate, prevent, and seek appropriate intervention for trans-
plant related medical and social issues. A quality assessment ques-
tionnaire was developed to assess retention of pediatric SCT dis-
charge education. The aim was to (1) determine the feasibility of
administering a quality assessment questionnaire following SCT
education to caregivers in pediatric SCTs and (2) correlate admin-
istration with re-admission rates in the ﬁrst 100 days post SCT.
Methods: The questionnaire was randomly introduced to a group
of 13 caregiver(s) prior to discharge. Twelve non-consecutive care-
givers served as the control group. The questionnaire consisted of
10 multiple-choice questions for autologous and 15 for allogeneic.
Questions were directed at recalling the education they received.
Upon completion, all answers were reviewed with the caregiver(s).
Any incorrect answers were reviewed and the correct answer and
rationale provided. Re-admission rates were monitored in both
groups for the ﬁrst 100 days. Results: Twenty-ﬁve patients (12
control; 13 test subjects) were analyzed during a 17 month period,
March 2004 to July 2005. Compliance was 100% in the test group.
Patient age ranged from 19 months to 17 years; there were 18
males and 7 females. The test group consisted of 2 autologous
PBSCT (peripheral blood), 2 MSD (matched sibling) BMT, 3
MSD PBSCT, and 6 URD (unrelated donor) BMT. The control
group consisted of 2 autologous PBSCT, 5 MSD PBSCT, and 5
URD BMT. The test group re-admission rate was 5/13 (38%).
The control group re-admission rate over the same period was
9/12 (75%). Staff variables between the 2 groups were similar.
Conclusions: Utilization of this tool decreased the incidence of
re-admission. This study suggests there is value in development of
a quality assessment tool assessing the impact of transplant related
education for patient caregiver(s) prior to discharge. There is a
trend toward decreased re-admissions in the early post-transplant
period and may translate into less cost, better care and comfort for
the patient. Continued assessment of this in a larger cohort is
planned over an extended period to determine the beneﬁts of this
tool.
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RECOGNIZING INDICATIONS FOR PHOTOPHERESIS IN ACUTE AND
CHRONIC GRAFT-VERSUS-HOST DISEASE PATIENTS
Graham, H.J., Wade, J.C., Rizzo, J.D., Hari, P., Miels, S.,
Gruling, R.J., Sorensen, S.H. 1. Medical College of Wisconsin, Milwau-
kee, WI; 2. M. D. Anderson, Houston, TX.
Introduction: Extra Corporal Photopheresis (ECP) is currently
being used as an effective treatment for patients with Acute and
Chronic Graft-versus-Host Disease (GVHD). Treatment has been
initiated as early as 24 hours after conﬁrming the Graft-versus-
Host Disease to be refractory to corticosteroids. Although there is
no standard treatment for Chronic Graft-versus-Host Disease,
ECP has been utilized as treatment with promising results. Meth-
ods: Cumulative treatment records for patients with Acute and
Chronic Graft-versus-Host Disease that received photopheresis
were retrospectively reviewed. Indications, frequency, and appro-
priateness of photopheresis treatment were analyzed. Although
there were indications of improvement in patients with Acute and
Chronic Graft-versus-Host Disease while receiving photopheresis
treatments, it was difﬁcult to quantify positive or negative changes
in the patients’ physical assessment. It is important to recognize
early indications of Graft-versus-Host Disease in the allogeneic
blood and marrow transplant (BMT) population. Presented is an
assessment tool to facilitate recognition and follow-up of physical
indicators in patients with Acute and Chronic Graft-versus-Host
Disease (GVHD). This assessment tool was developed following
discussions with physicians and nurses in an effort to prospectively
quantify the response to therapeutic modalities. Additionally, this
tool will assist in identifying time of response and beneﬁts of
treatments. This tool is being validated prospectively on patients
currently undergoing ECP. Once validated, the instrument will be
placed in routine use. The ultimate goal is to develop a tool to
assist the clinician in providing an initial and ongoing physical
assessment both before and during photopheresis treatment. This
tool can assist in identifying improvements or changes in the
patient’s Acute or Chronic Graft-versus-Host Disease status.
Results and conclusion will be presented.
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PERIPHERAL BLOOD CD34 ENUMERATION AS PREDICTOR FOR AU-
TOLOGOUS HEMATOPOIETIC PROGENITOR CELL (HPC) COLLECTION
IN CHILDREN
Daum, C.D., Klinger, E.F., Neudorf, S.M., Sloan, V., Nourani, A.,
Casacchia, C. Children’s Hospital of Orange County, Orange, CA.
Purpose: The ability to accurately predict the collection of
adequate numbers of CD34 cells in children can minimize the
unnecessary placement of apheresis catheters and stem cell collec-
tions. We hypothesize that the numbers of peripheral blood
CD34 cells will predict successful collection of HPCs in children
and are a more accurate predictor of successful collection than
white blood count. Methods: We studied 28 potential candidates
for autologous stem cell transplantation. Diseases included neuro-
blastoma (n  7), medulloblastoma (n  8), non-Hodgkin’s lym-
phoma (n  4), acute promyelocytic leukemia (n  1), other solid
tumors (n  8). The age range of the patients was 11 months–20
years. All received chemotherapy followed by 10 mcg/kg/day G-
CSF (24), or GM-CSF (1), or G-CSF  GM-CSF (2), or
G-CSF  IL-11 (1). Peripheral blood counts were monitored a
minimum of twice weekly. When the WBC 	 1000/ul, peripheral
blood CD34 cells were enumerated by ﬂow cytometry. Apheresis
was initiated when the peripheral blood CD34 count was 	10/
mm3. Apheresis was performed with the goal of collecting 5 
10e6 CD34 cells/kg. Results: Twenty-two of 28 patients had
	10 CD34 cells/ul prior to apheresis. Three patients had CD34
counts between 5-10/ul and 3 patients had CD34 counts 	5/ul.
The median CD34 count for all patients was 23.5/ul (range 2-400).
Twenty-one of 22 patients with 	10 CD34 cells/ul had had 5 
10e6 CD34 cells/kg collected and one patient reached 4.8 
10e6 CD34 cells/kg after 2 collections. Patients with 	10
CD34 cells/ul required a mean of 1.41 collections to reach the
goal of 5 10e6 CD34/kg. All patients whose CD34 count was
5-10 achieved their target goal of 5  10e6 CD34 cells/kg in a
mean of 3.33 collections. Only 1 of 3 patients with 5 CD34
cells/ul reached the goal of 5  10e6 CD34 cells/kg although in
all 3 cases, 	1  10e6 CD34 cells/kg were collected. Twenty-
eight of 28 patients had a WBC 	1000/ul prior to collection and
the WBC did not correlate with the numbers of circulating
CD34 cells. Conclusions: We found that starting apheresis
when the CD34/ul was 10 consistently resulted in meeting the
target goal of collecting 	 5  10e6 CD34 cells/kg and that
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circulating numbers of CD34 cells was a better predictor of
successful mobilization than WBC. Our observation that 3/3 pa-
tients who had 5-10 CD34 cells/ul were also successfully col-
lected suggests that it may be possible to lower the start of collec-
tion to when the CD34 count is 	5/ul.
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HEART SUCCESS WITH BLOOD AND MARROW TRANSPLANT PATIENTS:
A MULTIDISCIPLINARY APPROACH FOR CONGESTIVE HEART FAILURE
PATIENTS
Meyers, A.L., Kulma, A., Johnston, P., Woods, M., Fadol, A. M. D.
Anderson Cancer Center, Houston, TX.
By 2010, it is estimated that the American population aged 65 or
older will increase to over 40 million individuals. This will result in
an increase in the average age of the Blood and Marrow Transplant
population. Increased age translates into co- morbid conditions
that contribute to a signiﬁcant proportion of morbidity and mor-
tality. One example of this includes cardiovascular conditions that
patients bring with them at an increasing rate as they advance in
age. The average rates of cardiovascular events rise from 7 per
1000 men ages 35-44 to 68 per 1000 men ages 85-94 with nar-
rowing gaps with advancing age, and comparable rates occur 10
years later in life for women. Congestive heart failure (CHF) is one
of those cardiovascular co-morbid conditions that this patient pop-
ulation continues to bring into the transplant setting or is devel-
oped as a result of treatment. CHF affects 1.5-2% of the popula-
tion and increases 6-10% in people greater than 65 years of age. In
2003, more than 400 patients were hospitalized at the comprehen-
sive cancer center with a discharge diagnosis of CHF totaling a cost
of 36 million dollars. Cancer patients with heart failure can have
improved clinical outcomes. To improve clinical outcomes of these
patients, we have teamed together with Cardiology and have im-
plemented a Heart Success Program on the 52-bed inpatient unit.
The program entails education of the staff and patients about the
symptoms of CHF, the importance of daily weights, medications,
walking, energy conservation, and nutrition. The program is a
multidisciplinary approach including Pharmacy, APNs, Nursing,
Rehabilitation Services, Social work, Case Management, and Nu-
trition. The goals for the staff utilizing the heart success program
include increasing nurses’ awareness of the pathophysiology and
pharmacology of CHF, being more proactive in its recognition,
and identifying patients eligible for the program. The overall goals
are to have a reduction in hospital admissions for heart failure
exacerbation, decrease the length of stay and healthcare dollars
spent. Weekly rounds are conducted with Cardiology to review the
CHF patients. A case will be presented.
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CLINICAL NURSE RESOURCE: A NEW ROLE DESIGNED TO SUPPLE-
MENT VACANT CLINICAL NURSE SPECIALIST POSITIONS
Johnston, P.A., Meyers, A., Rivera, Z., Causton, C., Davis, L. The
University of Texas M. D. Anderson Cancer Center, Houston, TX.
Clinical Nurse Specialists (CNS) perform a critical role in lead-
ing efforts to improve outcomes affecting the oncology patient.
Through direct intervention, promotion of clinical assessment
skills, critical thinking, advanced clinical skills, and knowledge, and
interactions with the interdisciplinary team, the CNS works to
advance oncology nursing practice as direct care providers, con-
sultants, educators, patient, and system advocates, team coordina-
tors, program designers, and/or researchers. With the downsizing
of the CNS role in hospital and institutional settings, this has led
to a steady decline in the number of applicants entering CNS
academic programs. As a result, institutions that value the CNS
role, and the expertise they provide in highly complex patient care
environments, have experienced long-standing vacancies. Due to
the inability to ﬁll two vacant CNS positions on the Blood and
Marrow Transplant Unit (BMT), a method was undertaken to
identify and recognize experienced clinical nurses who could prac-
tice as unit resources and contribute to the mentoring, support, and
development of patient care providers and evidence-based quality
indicators on the inpatient unit. The Clinical Nurse Resource
(CNR) position was developed to address this need. A position
description including essential functions in clinical practice, edu-
cation, collaboration/consultation, research/quality improvement,
and leadership was formulated. Performance criteria in clinical
practice included serving as a clinical expert in BMT and promot-
ing excellence in clinical nursing practice through assessment and
interaction with staff and the interdisciplinary team. Education
incorporated providing educational opportunities to develop and
enhance performance, problem-solving, and critical thinking. Col-
laboration/consultation involved collaborating and consulting with
the interdisciplinary team to improve patient care delivery. Re-
search included the identiﬁcation and participation in researchable
patient problems or clinical inquiry projects. Outcomes of the
CNR positions were documented on a developed evaluation tool.
Value of the CNR position was immediately achieved with signif-
icant positive outcomes. Some of these included mentorship/
coaching of new BMT clinical staff and an evidence-based research
project to reduce the incidence of falls on the unit. The CNR
position on the inpatient BMT unit has proven to be beneﬁcial as
an alternative to fulﬁll the desired role of the CNS.
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UNMASK THE PEDIATRIC ALLOGENEIC TRANSPLANT PATIENT: A SIN-
GLE CENTER’S EXPERIENCE ON THE USE OF FLUCONAZOLE FOR
ANTIFUNGAL PROPHYLAXIS IN PATIENTS NOT USING FACE MASKS
POST TRANSPLANT
Gourde, J.A., Trotz, B.A., Henry, N., Rodriguez, V., Khan, S. Mayo
Eugenio Litta Children’s Hospital, Rochester, MN.
Many transplant centers require pediatric hematopoietic alloge-
neic transplant patients to wear a face mask until day 100 or
longer. Unlike most transplant centers, our allogeneic recipients
are not required to wear a face mask post-transplant. Our experi-
ence indicates that with the use of ﬂuconazole as standard antifun-
gal prophylaxis it is not necessary to require our patients to wear
face masks post-transplant. Fluconazole (Diﬂucan) dosed at 3-5
mg/kg daily is started on the day of admission pre-transplant and
discontinued once ANC 	 500 times 3 days (engraftment). Pa-
tients with graft-versus-host disease (GVHD) continue to receive
antifungal prophylaxis with ﬂuconazole while on immunosuppres-
sive therapy. We conducted a retrospective chart review of 22
pediatric allogeneic hematopoietic cell transplant (HCT) patients
from 1999-2004, which revealed no reported occurrences of fungal
infections. The patients were treated prophylactically with Diﬂu-
can. Four patients were changed to Ambisome due to recurrent
fevers with negative cultures, and 1 was changed due to interaction
between Diﬂucan and Tacrolimus. Patients were not required to
wear a face mask post-transplant. Therefore, we can speculate that
not wearing a mask does not increase the risk of fungal infections
in pediatric allogeneic HCT. Cases need to be evaluated on an
individual basis, including risk factors and conditioning regimens.
We advocate for larger studies to be completed regarding this
topic.
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THE BLOOD AND MARROW TRANSPLANTATION BUSINESS CENTER
THAT MAKES A DIFFERENCE IN THE PROCESSING OF BMT PATIENTS
Hontiveros, R.L., Cruz, E.D., Adornetto-Garcia, D. UT M. D. Ander-
son Cancer Center, Houston, TX.
The complexity of the Blood and Marrow Transplantation
(BMT) ﬁnancial process is usually a challenging hurdle for patients
during their treatment. At one of the largest transplant centers in
the country, a multidisciplinary team has developed a process that
enables patients to navigate this aspect of their treatment with ease.
The BMT Business Center (BC) was created to secure autho-
rization for transplantation from insurance companies. The ﬁ-
nancial process covers referrals and consultation from point of
access to admission. To accomplish this, each BC team member
has expertise in their role and is accountable for their portion of
the process. The BC is composed of a Patient Access Supervisor,
a Patient Access Appeals/Denials Coordinator (PADAC), and 4
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